Capital Investment Services of America Inc. Acquires 3,386 Shares of Illumina, Inc. (NASDAQ:ILMN)

Capital Investment Services of America Inc. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,147 shares of the life sciences company’s stock after purchasing an additional 3,386 shares during the period. Capital Investment Services of America Inc.’s holdings in Illumina were worth $9,027,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. HighMark Wealth Management LLC acquired a new stake in shares of Illumina during the first quarter worth approximately $33,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Illumina during the first quarter worth approximately $33,000. Clearstead Trust LLC increased its holdings in shares of Illumina by 125.7% during the first quarter. Clearstead Trust LLC now owns 158 shares of the life sciences company’s stock worth $37,000 after buying an additional 88 shares in the last quarter. BOKF NA acquired a new stake in shares of Illumina during the first quarter worth approximately $38,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Illumina by 64.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 194 shares of the life sciences company’s stock worth $39,000 after buying an additional 76 shares in the last quarter. Institutional investors own 92.17% of the company’s stock.

Insider Activity

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $200.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 46,522 shares of the company’s stock, valued at approximately $9,304,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 1,500 shares of company stock valued at $278,560. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ILMN shares. Citigroup dropped their price objective on shares of Illumina from $180.00 to $150.00 and set a “sell” rating for the company in a report on Thursday, August 10th. Bank of America lowered their price target on shares of Illumina from $230.00 to $210.00 in a report on Thursday, August 10th. Evercore ISI reissued an “outperform” rating and issued a $240.00 price target on shares of Illumina in a report on Friday, September 1st. HSBC lowered their price target on shares of Illumina from $270.00 to $235.00 and set a “buy” rating for the company in a report on Monday, August 14th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Illumina from $235.00 to $190.00 and set a “neutral” rating on the stock in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $236.05.

Illumina Stock Down 2.9 %

Shares of Illumina stock traded down $4.34 during trading hours on Friday, reaching $146.15. 3,543,451 shares of the company’s stock were exchanged, compared to its average volume of 1,414,951. The company has a 50 day moving average of $174.51 and a two-hundred day moving average of $197.06. Illumina, Inc. has a fifty-two week low of $145.14 and a fifty-two week high of $248.87. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.23. The stock has a market cap of $23.14 billion, a P/E ratio of -5.49, a P/E/G ratio of 8.15 and a beta of 1.12.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Wednesday, August 9th. The life sciences company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.30. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.57 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 0.83 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.